Tyrogenex
CompanyUnited States
Tyrogenex develops one asset, in phase 2, discontinued (X-82 in age-related macular degeneration). Mostly small molecule acting on PDGFRB, PDGFRA and FLT1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2, discontinued
- 3
- Trials
- 0
- Signals
Pipeline
1Dual inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor kinases
Phase 2, discontinued, Small molecule, PDGFRB, PDGFRA, age-related macular degeneration, exudative age-related macular degeneration
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials5
- Similar companies6